Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
Conclusion: Hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Drugs & Pharmacology | Gleevec | Heart | Hypertension | Leukemia | Nilotinib | Science | Study | Tasigna | Toxicology